Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(12):33 J Psychopharmacol. 2014 11-Apr;():. 10.1177/0269881114548296What this means for my practice?
Psilocybin appears to be safe and effective in accompanying a smoking cessation program for the purposes of quitting smoking. With the results of this pilot study, randomized comparative studies can be designed to further assess the efficacy of psilocybin on smoking cessation.
Study Summary
In a pilot case series study, 15 nicotine-dependent smokers were given either a moderate (20mg/70kg) or high (30mg/70kg) dose of psilocybin alongside a 15-week smoking cessation protocol. Biomarkers of smoking status (urinary cotinine, breath CO) and self-reported measures of smoking were evaluated 6 months after treatment. At 6 months follow-up outcomes indicated 12 of 15 participants had seven-day point prevalence abstinence.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
